Skip to content
Log in
Sponsored AI Networking Cookbook: Practical recipes for AI-assisted network automation and development AI Networking Cookbook: Practical recipes for AI-assisted network automation and development

Author

J. Chaft

h-index 68 View on Semantic Scholar

We have 7 of 364 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Sep 2026

Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial

CHORUS (NCT04905316) was an open-label, non-randomized, single-arm phase I/II trial of the anti-IL-1beta monoclonal antibody canakinumab given with concurrent chemoradiotherapy and continued with anti-PD-L1 durvalumab consolidation in unresectable stage III non-small cell lung cancer. The primary endpoint was 24-month...

N. Shaverdian, M. Offin, N. Toumbacaris et al. · 0 citations
Open access Sep 2026

2026 Revised Recommendations of The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer.

BACKGROUND Diagnosis, staging, and treatment of early-stage lung cancer remains an important area of thoracic surgical oncology. The previous AATS expert consensus document, published in 2023, reflected critical recommendations for the workup and management of this disease, including the adoption of chemoimmunotherapy...

B. Kidane, M. Bott, Jonathan D. Spicer et al. · 0 citations
Open access Aug 2026

Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network E4512): a phase 3 trial

It is suggested that crizotinib should not be recommended as an adjuvant therapy for patients with resected, early-stage ALK-positive NSCLC and that crizotinib should not be recommended as an adjuvant therapy for patients with resected ALK-positive NSCLC.

D. E. Gerber, Yating Wang, C. Langer et al. · 2 citations
Open access Oct 2026

SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy.

More than half of patients with early-stage non-small cell lung cancer (NSCLC) experience recurrent disease following definitive therapy. Targeted therapies have demonstrated significant and clinically meaningful benefit in EGFR-, ALK-, or RET-driven early-stage NSCLC. There are, however, no approved therapies for earl...

J. Chaft, Jay M. Lee, Suresh Senan et al. · 0 citations
Aug 2026

Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.

BACKGROUND Adding perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved survival outcomes compared with neoadjuvant chemotherapy and surgery alone in participants with early-stage non-small-cell lung cancer (NSCLC) in the phase 3, randomized KEYNOTE-671 study. We report results from KEYNOTE-671...

H. Wakelee, J. Spicer, S. Gao et al. · 1 citation
Review Open access Sep 2026

Early-stage non-small-cell lung cancer: emerging treatments and evolving challenges.

The treatment of early-stage non-small-cell lung cancer (NSCLC) has evolved substantially in recent years. For decades, curative-intent surgery followed by platinum-based chemotherapy remained the standard of care (SOC), despite delivering only modest gains in long-term survival. Current evidence from randomised trials...

Jordi Remon, T. Cascone, S. P. Saw et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.